Avalon GloboCare (NASDAQ:CHGA – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($3.53) earnings per share for the quarter, FiscalAI reports.
Avalon GloboCare Stock Down 16.4%
Shares of CHGA stock traded down $0.17 during trading hours on Monday, hitting $0.89. 48,092 shares of the company’s stock traded hands, compared to its average volume of 326,898. The stock’s 50 day simple moving average is $1.75 and its 200 day simple moving average is $7.06. The stock has a market cap of $992,656.00, a PE ratio of -0.06 and a beta of -0.15. Avalon GloboCare has a 12 month low of $0.69 and a 12 month high of $37.65.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 24th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
Avalon GloboCare Company Profile
Avalon GloboCare Corp. is a biotechnology company historically focused on developing cell-based technologies, regenerative medicine applications and precision-medicine solutions. Its work has included research and development involving cellular therapies, immunotherapy and other platforms intended to support the treatment of serious diseases. The company’s reported activities have included the development of CAR-T and other cell-therapy approaches, exosome-related technologies, and diagnostic and biobanking services.
Read More
- Five stocks we like better than Avalon GloboCare
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.
